GlySure Limited, an Abingdon, UK-based developer of in-hospital continuous blood glucose monitoring systems, has completed a $13.6m second close of its Series C financing round.
Backers include Amadeus Capital Partners, Chester Investments, Delta Partners, Morningside Ventures and Frank Bonsal, Jr.
The company, which has raised $22.4m in venture capital to date, intends to use the funding to complete clinical trials in support of U.S. and European regulatory clearance.
Led by Chris Jones, CEO, and Bill Moffitt, Chairman, GlySure is developing its continuous glucose monitoring (CGM) technology, which is designed to facilitate Tight Glycemic Control (TGC) in the intensive care unit (ICU).
The company’s products are not approved for use in the U.S. or Europe.